FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes

1.08x

No

6.29x

$4,012 vol1 market

Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027

2.40x

Before Mar 1, 2027

1.48x

$19,050 vol5 markets

Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.01x

No

3.29x

$8,279 vol1 market

Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before 2027

2.29x

Before November

4.73x

$99,053 vol2 markets

Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes

1.14x

No

4.73x

$1,673 vol1 market

Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes

2.46x

No

1.57x

$9,763 vol1 market

Medicine

Will the FDA approve CagriSema?

Before Jan 1, 2027

1.33x

Before Jul 1, 2027

1.19x

$5,730 vol4 markets

Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027

2.01x

Before Jan 1, 2028

1.09x

$38,962 vol5 markets

Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December

1.83x

before 2027

1.57x

$22,825 vol5 markets

Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes

1.16x

No

4.31x

$796 vol1 market

Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.23x

No

3.52x

$1,117 vol1 market

Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before November

1.65x

before 2027

1.26x

$20,756 vol5 markets

Eli Lilly

Will the FDA approve VERVE-102?

Before 2030

1.70x

Before 2031

1.42x

$1,733 vol6 markets

Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before July 2027

1.08x

Before 2028

1.08x

$6,234 vol3 markets

Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.07x

No

7.85x

$831 vol1 market

Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.08x

No

6.74x

$2,806 vol1 market

Tech & Science

Tech & Science

Medicine

Medicine

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

When will the FDA reclassify BPC-157 to Category 1?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Will the FDA approve a cure for Type 1 diabetes before 2033?

Will the FDA approve CagriSema?

Will the FDA approve retatrutide?

When will Beam Therapeutics submit a BLA for Risto-cel?

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

When will Compass Pathways submit a NDA for COMP360 psilocybin?

Will the FDA approve VERVE-102?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

When will the FDA reclassify BPC-157 to Category 1?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Will the FDA approve a cure for Type 1 diabetes before 2033?

Will the FDA approve CagriSema?

Will the FDA approve retatrutide?

When will Beam Therapeutics submit a BLA for Risto-cel?

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

When will Compass Pathways submit a NDA for COMP360 psilocybin?

Will the FDA approve VERVE-102?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)